GLP-1 Prescriptions for Young Children Rose Sharply
As off-label use grows, families and doctors are navigating weight management options for children aged 8 to 11.
Updated on Sept. 21, 2026 in Weight Loss
Live Poll
Do you trust the use of off-label weight-loss drugs for children under 12?
Prescriptions for GLP-1 receptor agonists among children aged 8 to 11 increased 310-fold between 2019 and 2026. While these medications are currently FDA-approved for weight management only for those aged 12 and older, clinicians are increasingly using them off-label for younger patients.
Why it matters
The rise in off-label prescribing reflects a growing effort by families and doctors to address severe obesity and its related health complications earlier in childhood. This shift highlights the urgent need for more clinical data to guide safe and effective care for younger populations.
A study of electronic health records for over 3.5 million children aged 8-11 found that annual prescribing rates for GLP-1 receptor agonists grew from 0.03% in 2019 to 9.3% in 2026. While preliminary evidence suggests safety for daily liraglutide in this age group, semaglutide data is pending.
The players
FDA
The federal agency responsible for regulating medication safety and authorizing age-specific approvals for drug therapies.
The details
GLP-1 receptor agonists are typically used off-label for children with severe obesity when standard behavioral and lifestyle interventions have failed to produce results. Clinicians evaluate individual risk-benefit ratios before opting for these medications, particularly for patients facing significant comorbidities. The decision-making process often involves weighing the potential health benefits against the uncertainties of using these drugs outside of established age-based approvals.
Timeline
2019: Annual prescribing rate for GLP-1 agonists was 0.03%.
2026: Annual prescribing rate reached 9.3%.
November 2026: Results for a semaglutide study in children aged 6-11 are expected.
Health Landscape
The surge in off-label prescriptions marks a significant departure from standard pediatric obesity treatment, which has historically relied on lifestyle modifications. This shift highlights a widening gap between clinical practice and current FDA pediatric weight management approval standards.
If your child is experiencing severe obesity, discuss the current status of pediatric weight management options and the risks of off-label medication use with your pediatrician. It is important to ask your doctor about the latest research findings before considering any medical treatment change.
The takeaway
The trend toward earlier pharmacotherapy for childhood obesity emphasizes the importance of ongoing research into long-term effects. Families should prioritize conversations with their pediatrician regarding medically supervised, evidence-based management plans for children.
What happens next
Results from a large study investigating the use of semaglutide in children aged 6 to 11 are expected to be presented in November 2026.
Further reading
For more on evolving treatment strategies, visit our Weight Loss section.
Live Poll
Do you trust the use of off-label weight-loss drugs for children under 12?
